Compare Crispr Therapeutics AG (CRSP) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Schlumberger NV — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Schlumberger NV trades at $49.1 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 14.9× Crispr Therapeutics AG's market cap, and Schlumberger NV pays a 2.41% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Schlumberger NV for 99 Days on average.
| CRSP | SLB | |
|---|---|---|
Market Cap | $4.88B | $72.69B |
Volume | 2,861,747 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $74.92 | $60.10 |
52-Week Low | $44.34 | $31.72 |
Typical Hold Time | 77 Days | 99 Days |
Enterprise Value | $3.30B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
SLB trades at $47.96, down 4.08% on the day, amid a bearish technical signal. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Recent contract wins in the Rovuma Basin, Saudi Arabia, and Oman bolster revenue visibility. Cash flow from operations remains strong at $6.49B for 2025, though net cash flow was negative due to financing activities.
Analyst consensus is bullish with an 84.85% buy rating and a $64.58 price target, implying significant upside. Risks include exposure to oil price volatility and recent profit margin compression. The stock's current valuation metrics, including a P/E of 23.89, appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
